AVIR logo

ATEA PHARMACEUTICALS INC

AVIRNASDAQ
🏆 #3173 by market capEarnings Nov 5US Equity
$4.27▲ $0.08 (+2.03%)
Pre-market · at close
🔔
Track AVIR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.0%
7d▲ 5.7%
14d▼ 5.8%
30d▼ 17.3%
ytd▲ 19.0%
1y▲ 30.4%
🏦Market Cap
$342M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$4.16 – $4.27
52-Week Range
$2.87 – $6.45
Volume (shares)
43,607
Avg Volume (shares)
—
Shares Outstanding
80.2M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-2.0
P/S Ratio
0.0x
EPS (TTM)
$-2.06
Dividend Yield
0.00%
Dilution (1yr)
−7.5%
AVIR logo

ATEA PHARMACEUTICALS INC

AVIR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$181M▼ −6.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$132M▼ −2.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
78.1M▼ −7.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$95M▲ +$32M YoY
StockOtter · stockotter.space

About ATEA PHARMACEUTICALS INC

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.